C7A.00
BillableMalignant carcinoid tumor of unspecified site
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C7A.00 an HCC code?
Yes. C7A.00 maps to Lymphoma and Other Cancers under the CMS-HCC V28 risk adjustment model (and Breast, Prostate, and Other Cancers and Tumors under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C7A.00
For C7A.00to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C7A.00 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C7A.00 is the ICD-10-CM diagnosis code for malignant carcinoid tumor of unspecified site. A rare type of cancer called carcinoid tumor that starts in neuroendocrine cells, but the exact location in the body is not specified. C7A.00 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neuroendocrine tumors (c7a).
Under the CMS-HCC V28 risk adjustment model, C7A.00 maps to Lymphoma and Other Cancers (HCC 21) with a community, non-dual, aged base RAF weight of 0.671. Under the older CMS-HCC V24 model, C7A.00 maps to Breast, Prostate, and Other Cancers and Tumors (HCC 12) with a community, non-dual, aged base RAF weight of 0.150. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Use this code only when the primary site of the carcinoid tumor cannot be determined or is truly unspecified. Because C7A.00 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C7A.00 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Use this code only when the primary site of the carcinoid tumor cannot be determined or is truly unspecified
- •If any anatomical site information is available, use a more specific C7A code rather than this unspecified code
Clinical Significance
Malignant carcinoid tumor of unspecified site represents a neuroendocrine neoplasm with malignant behavior whose primary location cannot be identified. Carcinoid tumors are slow-growing neuroendocrine tumors that can produce hormones causing carcinoid syndrome. Using the unspecified code suggests the primary site has not been located despite workup, which occurs in a small percentage of neuroendocrine tumor presentations.
Documentation Requirements
- ✓Documentation of malignant behavior — invasion, metastasis, or high-grade features
- ✓Workup performed to identify the primary site — CT, MRI, octreotide scan, PET
- ✓Biochemical markers — chromogranin A, 5-HIAA (5-hydroxyindoleacetic acid), serotonin levels
- ✓Pathology confirming neuroendocrine differentiation and malignant grade
- ✓Whether carcinoid syndrome is present — flushing, diarrhea, bronchospasm, cardiac involvement
Commonly Confused Codes
- •C7A.010-C7A.098 — Site-specific malignant carcinoid tumors; always use a specific anatomical code when the primary site is known
- •D3A.00 — Benign carcinoid tumor of unspecified site; benign versus malignant behavior must be clearly documented
- •C7B.00-C7B.09 — Secondary neuroendocrine tumors; metastatic carcinoid deposits use C7B codes, not C7A
- •E34.0 — Carcinoid syndrome; the syndrome itself is coded separately from the tumor